Fortis Life Sciences

Fortis Life Sciences is a life sciences holding company established in August 2020 by a team of industry veterans in partnership with global growth equity investor Summit Partners. Headquartered in Waltham, Massachusetts, Fortis was created to build a vertically integrated platform of specialized reagent, diagnostics, and molecular biology businesses. The company acquires and grows founder-led life science companies, providing them with capital, operational expertise, and shared infrastructure to scale. Fortis's portfolio spans antibodies, diagnostic components, molecular biology reagents, engineered nanoparticles, and viral vector platforms, serving biopharma, diagnostics, research, and applied technology customers globally. Key subsidiaries include Bethyl Laboratories (antibodies and proteins, acquired October 2020), nanoComposix (nanomaterials, June 2021), Empirical Bioscience (genomic reagents, September 2021), Arista Biologicals (lateral flow diagnostics, December 2021), Abcore (VHH/nanobody discovery, February 2022), International Point of Care (lyophilization, February 2023), and Vector Biolabs (viral vectors, March 2023). The company operates six North American manufacturing and R&D locations, serves 1,000+ customers across 65 countries, and has generated over 30,000 citations in peer-reviewed publications.